New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
04:55 EDTSNE, SNE, SNE, SNE, SNE, SCMP, SCMP, SCMP, SCMP, SCMP, PRGO, PRGO, PRGO, PRGO, PRGO, OMER, OMER, OMER, OMER, OMER, NBY, NBY, NBY, NBY, NBY, LMNS, LMNS, LMNS, LMNS, LMNS, HALO, HALO, HALO, HALO, HALO, CAJ, CAJ, CAJ, CAJ, CAJ, AKRX, AKRX, AKRX, AKRX, AKRX, AGN, AGN, AGN, AGN, AGN, ACL, ACL, ACL, ACL, ACL, ABT, ABT, ABT, ABT, ABTAmerican Society of Cataract and Refractive Surgery to hold a symposium
2014 ASCRS-SOA Symposium & Congress is being held in Boston, MA on April 25-29.
News For ABT;ACL;AGN;AKRX;CAJ;HALO;LMNS;NBY;OMER;PRGO;SCMP;SNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 17, 2015
09:25 EDTAGNIronwood slips after Synergy announces data on constipation drug
Shares of Ironwood (IRWD) are lower in pre-market trading after Synergy Pharmaceuticals (SGYP) announced top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses in adult patients with chronic idiopathic constipation. Plecanatide was safe and well tolerated at both doses, Synergy said, noting that the most common adverse event was diarrhea, which occurred in 5.9% of patients in 3.0 mg and 5.5% of patients in 6.0 mg dose groups. Ironwood’s competing Linzess drug had a 16% diarrhea rate for CIC patients, according to its FDA label. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). Ironwood shares are down 45c, or 3.7%, to $11.75 in pre-market trading.
09:16 EDTAGNAllergan buyout of KYTHERA boosts aesthetics portfolio, says BMO Capital
BMO Capital says Allergan's (AGN) buyout of KYTHERA (KYTH) builds out the company's aesthetics portfolio. KYTHERA's double chin treatment Kybella "could be a game changer in contouring," and there is no company better suited to make that happen than Allergan, BMO tells investors in a research note. The firm keeps an Outperform rating on Allergan with a $378 price target.
07:44 EDTAGNKYTHERA volatility low into Allergan acquiring for approximately $2.1B
Subscribe for More Information
07:21 EDTAGNGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
07:15 EDTAGNAllergan to host conference call
Conference call to discuss a definitive agreement to acquire KYTHERA Biopharmaceuticals-(KYTH) will be held at 8:30 am on June 17. Webcast Link
07:04 EDTAGNAllergan to acquire KYTHERA for $75 per share, or $2.1B
Subscribe for More Information
07:03 EDTAGNAllergan agrees to acquire KYTHERA for $75 per share or approximately $2.1B
Subscribe for More Information
07:03 EDTAGNAllergan agrees to acquire KYTHERA for $75 per share or approximately $2.1B
Subscribe for More Information
07:02 EDTAGNAllergan to acquire KYTHERA for $75 per share, or $2.1B
June 16, 2015
16:59 EDTNBYNovaBay files to sell 16.34M shares of common stock for holders
Subscribe for More Information
16:44 EDTSNESony fails to have lawsuit from hacked former employees dismissed, Reuters says
Subscribe for More Information
14:39 EDTHALOHalozyme has a conference call hosted by JPMorgan
JPMorgan Analyst Fye will host a conference call with CEO Helen Torley on June 19 at 10 am.
14:12 EDTPRGO, ABTAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
11:51 EDTOMEROmeros pact a clever way to commercialize OMS103, says Wedbush
Subscribe for More Information
11:06 EDTPRGO, ABTTeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
09:21 EDTABT, PRGOMylan issues statement regarding Abbott's support for Perrigo transaction
Subscribe for More Information
09:10 EDTABT, PRGOAbbott confirms support for Mylan's proposed acquisition of Perrigo
Abbott (BT) confirmed its continued support for Mylan (MYL) N.V's growth strategy by stating its intent to vote its 14.5% stake in Mylan in favor of Mylan's proposed acquisition of Perrigo (PRGO). "We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its scale and breadth across critical distribution channels, broad and diverse portfolio, and commitment to patients and product quality strongly positions it for success in the years to come," said Abbott. "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan's standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders, and offers a clear path to completion. In light of these factors, we will be voting in favor of the Perrigo transaction."
08:16 EDTSNESony June volatility at 31 into E3Expo.com as shares near four-year high
Subscribe for More Information
07:03 EDTOMEROmeros enters into license agreement with affiliates of Fagron form OMS103
Subscribe for More Information
05:45 EDTAGNAllergan, Richter announce FDA has extended review period for cariprazine
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use